title: Protection against late-onset AIDS in macaques prophylactically immunized with a live simian HIV vaccine was dependent on persistence of the vaccine virus.
abstract: This is a 5-year follow-up study on 12 macaques that were immunized orally with two live SHIV vaccines, six with V1 and six with V2. All 12 macaques became persistently infected after transient replication of the vaccine viruses; all were challenged vaginally 6 mo later with homologous pathogenic SHIV(KU-1). Two of the V1 group developed full-blown AIDS without evidence of vaccine virus DNA in tissues. The data on the 10 vaccinated survivors showed that all 10 became infected with SHIV(KU-1) and that DNA of both vaccine and SHIV(KU-1) viruses were present 6 mo postchallenge, with minimal replication of SHIV(KU-1). During the following 5 years, these animals remained persistently infected, but with only one of the two viruses. Six animals eliminated their vaccine virus after variable periods of time and four of these succumbed to reactivation of the challenge virus and AIDS. Five years after challenge, four latently infected animals, two with V2 and two with SHIV(KU-1), were reinoculated with SHIV(KU-1.) This resulted in transient superinfection and the animals promptly returned to their prechallenge status. Immunosuppression of the four animals 1 year later with Abs to CD8+ lymphocytes resulted in transiently productive replication of their respective latent viruses, and upon recovery of CD8+ lymphocytes, they reverted to their latent virus status. The major finding was that of eight animals that eliminated the vaccine virus, six developed AIDS. The two others harboring SHIV(KU-1) remain at risk for developing late-onset disease. The primary correlate against AIDS was persistence of the vaccine virus.
authors.affiliation: Marion Merrell Dow Laboratory of Viral Pathogenesis, Division of Infectious Diseases, Department of Microbiology, Molecular Genetics, and Immunology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
authors.forename: Glenn A
authors.initials: GA
authors.lastname: Mackay
authors.forename: Zhenqian
authors.initials: Z
authors.lastname: Liu
authors.forename: Dinesh K
authors.initials: DK
authors.lastname: Singh
authors.forename: Marilyn S
authors.initials: MS
authors.lastname: Smith
authors.forename: Sampa
authors.initials: S
authors.lastname: Mukherjee
authors.forename: Darlene
authors.initials: D
authors.lastname: Sheffer
authors.forename: Fenglan
authors.initials: F
authors.lastname: Jia
authors.forename: Istvan
authors.initials: I
authors.lastname: Adany
authors.forename: Kelvin H
authors.initials: KH
authors.lastname: Sun
authors.forename: Sukhbir
authors.initials: S
authors.lastname: Dhillon
authors.forename: Wu
authors.initials: W
authors.lastname: Zhuge
authors.forename: Opendra
authors.initials: O
authors.lastname: Narayan
mesh_terms: D000284:Administration, Oral; D000818:Animals; D018414:CD8-Positive T-Lymphocytes; D005260:Female; D005500:Follow-Up Studies; D007111:Immunity, Cellular; D007115:Immunization Schedule; D007117:Immunization, Secondary; D008212:Lymphocyte Depletion / Q000379:methods; D008254:Macaca nemestrina; D012367:RNA, Viral / Q000097:blood; D018449:SAIDS Vaccines / Q000276:immunology* / Q000627:therapeutic use; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control* / Q000821:virology; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000276:immunology / Q000627:therapeutic use; D014775:Virus Activation / Q000276:immunology; D017735:Virus Latency / Q000276:immunology*; D014779:Virus Replication / Q000276:immunology
chemical_list: D012367:RNA, Viral; D018449:SAIDS Vaccines; D014613:Vaccines, Attenuated